Immune Mechanisms of Rejection in Human Lung Allografts

NCT ID: NCT00861900

Last Updated: 2018-06-19

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 778 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 1998-01-31
• Study Completion Date: 2017-07-31

Brief Summary

The investigators have obtained compelling evidence that the development of anti-human leukocyte antigen (anti-HLA) antibodies against mismatched donor antigens significantly correlates with the development of bronchiolitis obliterans (BOS). Further, these anti-HLA antibodies are developed at least 15 months prior to any clinical evidence of BOS. This lag period between the development of anti-HLA antibodies and the onset of BOS gives us an opportunity to intervene to delay and/or prevent the development of BOS.

Conditions

Bronchiolitis Obliterans

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Eligibility Criteria

Inclusion Criteria

• Lung transplant recipient.

Exclusion Criteria

• Pregnant women,
• Prisoners, AND
• Anyone who is unable or unwilling to consent to this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

Washington University School of Medicine

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Thalachallour Mohanakumar, PhD

Role: PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Other Identifiers

HL056643

Identifier Type: -

Identifier Source: secondary_id

98-0977-201103312

Identifier Type: -

Identifier Source: org_study_id